Comparison of PSMA-based 18F-DCFPyL PET/CT to Conventional Imaging in the Evaluation of Subjects With Castration-Resistant Prostate Cancer
Active, no longer recruiting
Phase of Trial: Phase 0
Latest Information Update: 11 Oct 2017
At a glance
- Drugs 18F DCFPyL (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Diagnostic use
- 05 Oct 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.
- 05 Oct 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
- 05 Oct 2017 Status changed from recruiting to active, no longer recruiting.